Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters










Database
Language
Publication year range
1.
Transl Stroke Res ; 12(1): 72-86, 2021 02.
Article in English | MEDLINE | ID: mdl-32253702

ABSTRACT

The extracellular matrix fragment perlecan domain V is neuroprotective and functionally restorative following experimental stroke. As neurogenesis is an important component of chronic post-stroke repair, and previous studies have implicated perlecan in developmental neurogenesis, we hypothesized that domain V could have a broad therapeutic window by enhancing neurogenesis after stroke. We demonstrated that domain V is chronically increased in the brains of human stroke patients, suggesting that it is present during post-stroke neurogenic periods. Furthermore, perlecan deficient mice had significantly less neuroblast precursor cells after experimental stroke. Seven-day delayed domain V administration enhanced neurogenesis and restored peri-infarct excitatory synaptic drive to neocortical layer 2/3 pyramidal neurons after experimental stroke. Domain V's effects were inhibited by blockade of α2ß1 integrin, suggesting the importance of α2ß1 integrin to neurogenesis and domain V neurogenic effects. Our results demonstrate that perlecan plays a previously unrecognized role in post-stroke neurogenesis and that delayed DV administration after experimental stroke enhances neurogenesis and improves recovery in an α2ß1 integrin-mediated fashion. We conclude that domain V is a clinically relevant neuroprotective and neuroreparative novel stroke therapy with a broad therapeutic window.


Subject(s)
Brain/metabolism , Heparan Sulfate Proteoglycans/biosynthesis , Neurogenesis/physiology , Neuroprotection/physiology , Stroke/metabolism , Animals , Brain/drug effects , Brain/pathology , Cells, Cultured , Heparan Sulfate Proteoglycans/administration & dosage , Humans , Male , Mice , Mice, Inbred C57BL , Neurogenesis/drug effects , Neuroprotection/drug effects , Organ Culture Techniques , Protein Domains , Stroke/pathology , Stroke/prevention & control
2.
J Cereb Blood Flow Metab ; 39(6): 1026-1037, 2019 06.
Article in English | MEDLINE | ID: mdl-29171775

ABSTRACT

Chronic consumption of diets high in fat leads to obesity and can negatively affect brain function. Rodents made obese by long-term maintenance on a high-fat diet have worse outcome after experimental stroke. High-fat consumption for only three days does not induce obesity but has rapid effects on the brain including memory impairment. However, the effect of brief periods of high-fat feeding or high-fat consumption in the absence of obesity on stroke is unknown. We therefore tested the effect of an acute period of high-fat feeding (three days) in C57B/6 mice on outcome after middle cerebral artery occlusion (MCAo). In contrast to a chronic high-fat diet (7.5 months), an acute high-fat diet had no effect on body weight, adipose tissue, lipid profile or inflammatory markers (in periphery and the brain). Three days of high-fat feeding impaired glucose tolerance, increased plasma glucose and insulin and brain expression of the glucose transporter GLUT-1. Ischaemic damage was increased (48%) in mice fed an acute high-fat diet, and was associated with a further reduction in GLUT-1 in the ischaemic hemisphere. These data demonstrate that only a brief period of high-fat consumption has a negative effect on glucose homeostasis and worsens outcome after ischaemic stroke.


Subject(s)
Blood Glucose/metabolism , Diet, High-Fat/adverse effects , Homeostasis , Stroke/pathology , Animals , Glucose Intolerance , Glucose Transporter Type 1/metabolism , Male , Mice , Mice, Inbred C57BL , Time Factors
3.
J Cereb Blood Flow Metab ; 37(1): 85-96, 2017 01.
Article in English | MEDLINE | ID: mdl-26661237

ABSTRACT

Stroke is a disease in dire need of better therapies. We have previously shown that a fragment of the extracellular matrix proteoglycan, perlecan, has beneficial effects following cerebral ischemia via the α5ß1 integrin receptor. We now report that endothelial cell selective α5 integrin deficient mice (α5 KO) are profoundly resistant to ischemic infarct after transient middle cerebral artery occlusion. Specifically, α5 KOs had little to no infarct 2-3 days post-stroke, whereas controls had an increase in mean infarct volume over the same time period as expected. Functional outcome is also improved in the α5 KOs compared with controls. Importantly, no differences in cerebrovascular anatomy or collateral blood flow were noted that could account for this difference in ischemic injury. Rather, we demonstrate that α5 KOs have increased blood-brain barrier integrity (increased expression of claudin-5, and absent brain parenchymal IgG extravasation) after stroke compared with controls, which could explain their resistance to ischemic injury. Additionally, inhibition of α5 integrin in vitro leads to decreased permeability of brain endothelial cells following oxygen-glucose deprivation. Together, these findings indicate endothelial cell α5 integrin plays an important role in stroke outcome and blood-brain barrier integrity, suggesting that α5 integrin could be a novel therapeutic target for stroke.


Subject(s)
Brain Ischemia/pathology , Disease Susceptibility/chemically induced , Integrin alpha5/physiology , Stroke/etiology , Animals , Blood-Brain Barrier/metabolism , Brain Infarction/pathology , Claudin-5/biosynthesis , Disease Models, Animal , Endothelial Cells/metabolism , Infarction, Middle Cerebral Artery/complications , Infarction, Middle Cerebral Artery/pathology , Integrin alpha5/genetics , Mice , Mice, Knockout , Stroke/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...